AddLife AB (STU:1AD1) Notes Receivable: €0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1AD1 AddLife AB STU:1AD1
88 GF Score
Price €14.94
GF Value €13.28
! 5 Warning Signs
View Full Analysis

What is AddLife AB Notes Receivable?

AddLife AB STU:1AD1 +1.01% 88 Notes Receivable is €0.0 Mil as of Jun. 2026. GuruFocus rates STU:1AD1 with a GF Score™ of 88/100 and a GF Value™ of €13.28. The stock has 5 warning signs investors should review.

AddLife AB's Notes Receivable for the quarter that ended in Jun. 2026 was €0.0 Mil.

AddLife AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for AddLife AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AddLife AB Notes Receivable Chart

AddLife AB Annual Data
Trend Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AddLife AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:1AD1
88GF Score
AddLife AB STU:1AD1
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AddLife AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.0 Mil mean?
AddLife AB (STU:1AD1) has a Notes Receivable of €0.0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on AddLife AB and its competitors.
Is AddLife AB's Notes Receivable too high?
AddLife AB's current Notes Receivable is €0.0 Mil. Overall, AddLife AB has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's Notes Receivable compare to ISRG and BDX?
AddLife AB's Notes Receivable of €0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on AddLife AB and its competitors. AddLife AB's current Notes Receivable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
AddLife AB (STU:1AD1) has a current Notes Receivable of €0.0 Mil. The stock's GF Value™ is €13.28, compared to a current price of €14.94 — trading 12.5% above its estimated fair value. The current Notes Receivable is €0.0 Mil. AddLife AB's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For AddLife AB (STU:1AD1), the current Notes Receivable is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AddLife AB (STU:1AD1) Overvalued in 2026?

Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued. The current stock price of €14.94 is trading 12.5% above its estimated GF Value™ of €13.28.

Key valuation signals for STU:1AD1:

  • Notes Receivable: €0.0 Mil
  • GF Value™: €13.28 vs. price of €14.94 (12.5% above fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the STU:1AD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AddLife AB Business Description

Address Brunkebergstorg 5, Box 3145, Stockholm, SWE, 103 62
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
88GF Score

Get the complete analysis for STU:1AD1

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.94
Price
€13.28
GF Value